Risks associated with COVID-19 severity
New Disease Biomarkers Uncovered in MIS-C, COVID-19
Signatures associated with cellular injury and death differentiate MIS-C and COVID-19 in pediatric patients
Hereditary Angioedema Remains Challenge to Diagnose, Treat
Respondents cite economic issues related to treatment, which can be compounded for patients living in rural areas
Pediatric SARS-CoV-2, MIS-C Differed in Delta, Omicron Waves
Clinical severity was lower during omicron wave, and rate of incidental diagnoses was higher than during delta
Free Spike Antigen ID’d in Post-SARS-CoV-2 mRNA Vaccine Myocarditis
However, mRNA vaccine-induced immune responses did not differ for those who developed myocarditis and those who did not
MIS-C Seems More Common, Severe Than Previously Thought
Racial disparities seen in outcomes, including more cases in Black children as organ dysfunction increases
No Increase in Adverse Events Seen With COVID-19 Vaccination After MIS-C
Minor adverse events seen in 48.6 percent of patients, most often arm soreness and/or fatigue
New Surveillance Case Definition Developed for MIS-C
Four changes included in new case definition, including no required duration of subjective or measured fever
Blood Biomarker Linked to Incident VTE in COVID-19 Patients
Higher levels of soluble urokinase plasminogen activator receptor linked to incident venous thromboembolism independently of D-dimer
Cases of Kawasaki Disease in the U.S. Dropped During Pandemic
Kawasaki disease cases fell by 28 percent and remained low during periods of pandemic-related masking and school closures